Clinical Trial

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 6, 2025 (before its estimated May 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-14; most recent amendment 2025-06-03.
Status change: Recruiting → Active, Not Recruiting 2025-06-03
Status change: Not Yet Recruiting → Recruiting 2024-11-19
Trial Details
NCT Number NCT06601504
Lead Sponsor Hutchmed
Conditions Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Enrollment 61 participants
Start Date 2024-11-05
Primary Completion 2026-05-12 (estimated)
Study Completion 2026-11-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-06